_______________________________

Slides:



Advertisements
Similar presentations
Using an Independent Statistician to Support a Data Monitoring Committee Patrick D. OMeara, Ph.D. Pat OMeara Associates, Inc. FDA/Industry.
Advertisements

External Quality Assessments Frequently Occurring Findings Observed by The IIA QA Teams.
The Role of the Data Monitoring Committee Society for Clinical Research Associates Philadelphia, PA April 23, 2010.
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Collecting Citizen Input Management Learning Laboratories Presentation to Morrisville, NC January 2014.
Presentation of BE data in a product dossier Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
The Statisticians Role in Pharmaceutical Development
Elements of a clinical trial research protocol
National Commission for Academic Accreditation & Assessment Preparation for Developmental Reviews.
The BIM Project Execution Planning Procedure
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
1 Framework Programme 7 Guide for Applicants
1 Our Expertise and Commitment – Driving your Success An Introduction to Transformation Offering November 18, 2013 Offices in Boston, New York and Northern.
THE ROLE OF DSMB’s in CLINICAL RESEARCH Data and Safety Monitoring Monitoring.
Module N° 8 – SSP implementation plan. SSP – A structured approach Module 2 Basic safety management concepts Module 2 Basic safety management concepts.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
DATA MONITORING COMMITTEES: COMMENTS ON PRESENTATIONS Susan S. Ellenberg, Ph.D. Department of Biostatistics and Epidemiology University of Pennsylvania.
United States Department of Agriculture Food Safety and Inspection Service 1 National Advisory Committee on Meat and Poultry Inspection August 8-9, 2007.
1Presentation Name Pre-Marketing Safety Assessment: The Safety Review Guidance Armando Oliva, M.D. Associate Director for Policy Office of New Drugs.
Mass BioTech Council DMC Presentation Statistical Considerations Philip Lavin, Ph.D. October 30, 2007.
Ulla Lønberg – International Safety & Pharmacovigilance – H. Lundbeck A/S21-Feb-2007 Data Monitoring Committees.
Circuit Rider Training Program (CRTP) Circuit Rider Professional Association Annual General Meeting and Conference August 30, 2012.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Diagnostic reference levels in Medical Imaging. Concept and practice
Communication, monitoring and recruitment targets.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
Responsibilities of Sponsor, Investigator and Monitor
1 Transnational Partner Search Toolkit Transnationality Contact Points Meeting 30 September Warsaw.
Remote Site Initiation Visits
Investigator Training
Review of IT General Controls
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
Project Quality Management
Outline of pilot for support for disabled staff
Responsibilities of Sponsor, Investigator and Monitor
Project Management The Roles and Responsibilities of a Project Manager
MAINTAINING THE INVESTIGATOR’S SITE FILE
FDA’s IDE Decisions and Communications
Reportable Events & Other IRB Updates February 2017
SAMPLE Develop a Comprehensive Competency Framework
Within Trial Decisions: Unblinding and Termination
The International Plant Protection Convention
Watching From Above: The Role of the DSMB
Clinical Study Results Publication
Critical Reading of Clinical Study Results
NHLBI Perspective Yves Rosenberg, M.D, M.P.H.
Fundamentals of a Business Impact Analysis
Data Monitoring Committees: Current Issues and Challenges Some Discussion Points Jim Neaton University of Minnesota.
Engineering Processes
RST processes Session 5 Presentation 2.
CBP Biennial Strategy Review System
Statistical considerations for the Nipah virus treatment study
Data Monitoring committees and adaptive decision-making
Statistical considerations for the Nipah virus treatment study
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Leading Practice Implementation Guide
Principal Investigator ESTCP Selection Meeting
Leading Practice Implementation Guide
Preparing for a Stack Test
Plan your journey.
ESS Handbook on Radiation Protection Chapter 6 – Dosimetry
Internal Audit Who? What? When? How? Why? In brief . . .
NCIOM Task Force on a Perinatal System of Care
Hanna Gembarzewska, Monika Grabani
Principal Investigator ESTCP Selection Meeting
Draft revision of ISPM 6: National surveillance systems ( )
Planning Services Meeting Client Communications
Periodic Accounting Review Periodic Revenue Reconciliation
Natasa Rajicic, ScD July 31, 2019
Blinded Safety Monitoring In Clinical Trials and IND Safety Reporting: Challenges and Lessons Learned Barbara Hendrickson, M.D. Immunology Therapeutic.
Presentation transcript:

_______________________________ DSBS 30th May 2006, Annual Meeting _____________________________________ DMC – how and what should they evaluate? _______________________________ Bjarne Nielsen, Vice President Biometrics

DMC – Data Monitoring Committees General info Medicon is involved in DMCs for several clients and have a special group dedicated to DMC tasks. Medicon is involved either as a member of the DMC or as external statistician to perform statistical analysis for the DMC, keeping the client blinded for the trial. Medicon is at the moment involved in 12 DMC worldwide. 11-01-2019

DMC Group – staff at Medicon Bjarne Nielsen, MSc Statistics Vice President Biometrics Martin Eeg, MSc Statistics Senior Biostatistician Peter Meisels, MSc Statistics Senior Biostatistician Allan Prang, MSc Biology Senior Statistical Programmer Tony Awwad, MSc Economy Statistical Programmer Rita Schou, Executive Assistant Jesper Nelby Kristiansen, MSc Biology Senior Data Manager 11-01-2019

DMC – Data Monitoring Committees Typical Procedures An Independent experienced DMC is selected and a Charter is produced with input from DMC and protocol input is made. Open and closed sessions are prepared, a SAP is made showing deliverables (data packages) and timelines. A face-to-face meeting is held. During the trial, telecons or web-conf are held. The DMC receives data packages typically 3-5 working days after Medicon receives interim data. DMC requests additional or revised analyses or data presentations. 11-01-2019

Typical Procedures, continued DMC Data Handling Typical Procedures, continued Data sources: We receive data from various sources, e.g. Laboratories, Safety departments, Event committees, Study database, ECG readings, Fax forms. Timelines: Typically, we deliver the data package 3-5 days after receipt of (unclean) data. Web site: MUDA – Medicon Upload & Download Area. For easy exchange of information between DMC members. Personal Username and Password required in order to gain access to this site. 11-01-2019

DMC – Data Monitoring Committees What should the DMC do? – apart from recommending to either continue or stop the trial Ensure patient safety, Ensure patient safety, Ensure patient safety. Evaluate safety data and compare to control and/or expectations. Evaluate whether the conduct of the trial and the data quality are sufficient to make recommendations and ensure that ”patients are not waisted” on inconclusive trials due to sloppyness. Evaluate safety in relation to risk/benefit – requires often efficacy considerations, Ensure patient safety. 11-01-2019

DMC – Data Monitoring Committees What should the DMC do? – Evaluate safety Evaluate AEs and SAEs, critical events etc – often on a case-by-case basis. Evaluate other safety data like ECGs, laboratory data or mortality. Evaluate dose effects on the above mentioned data. How should they do that? Review data overview (descriptive summary tables and plots and stat.tests). Review case data. Use statistical stopping rules as guidance. Look for expected as well as unexpected findings. Look for trends, e.g across dose groups – even across trials!! 11-01-2019

DMC – Data Monitoring Committees What should the DMC do? – Data quality and study procedures Review data, missing data patterns and magnitude. Review study procedure appropriateness, e.g. randomisation bias, bias in censoring or sloppyness on crucial data collection points. Ensure comparabililty of data – issues relevant also in final reporting. 11-01-2019

DMC – Data Monitoring Committees What should the DMC do? – Risk / benefit evaluation Not sample size adjustment in order to reach efficacy conclusion. Basis for evaluation of risk, taking the benefit into account – requires hard endpoint data on efficacy – which may only be partly available – e.g. long time mortality measures. Often an issue for discussion. 11-01-2019

DMC – Data Monitoring Committees Conclusion A DMC must ensure patient safety Meet and discuss up front Find experienced members Plan, but be prepared for changes 11-01-2019

For further information on Medicon, please contact: Contact Details For further information on Medicon, please contact: Bjarne Nielsen, MSc Statistics Vice President, Biometrics Medicon Biometrics Datavej 24 P.O. Box 130 DK-3460 Birkerød Denmark Phone: + 45 4567 2278 Fax: + 45 7022 1571 e-mail: bn@medicon.dk www.medicon.dk 11-01-2019